

SUPPLEMENTAL MATERIAL

MS#: ATVB/2020/314845R1

COVID-19 in the Healthy Patient Population: Demographic and Clinical Phenotypic Characterization and Predictors of In-Hospital Outcomes

Diana Maria Ronderos Botero , MD (1)*, Alaa Mabrouk Salem Omar, MD, MSc, PhD (1,2,3)*, Haozhe Keith Sun, MD (1), Nikhitha Mantri, MD (1), Ked Fortuzi, MD (1), Yongsub Choi, MD (1), Muhammad Adrish, MD (1,2), Marin Nicu, MD (1,2), Jonathan N Bella, MD (1,2), Sridhar Chilimuri, MD (1,2).

* Both authors contributed equally

Author affiliation:

(1) Department of Internal Medicine, BronxCare Health System, Bronx, NY, USA

(2) Icahn School of Medicine at Mount Sinai, New York, NY, USA

(3) Department of Cardiovascular Medicine, Mount Sinai Saint Luke's Hospital, New York, NY, USA

Supplementary table 1: Demographic, Clinical, and laboratory characterization of all patients admitted with COVID-19 during the study period

	All patients (n=1207)
Age, years	61.9±15.7
Gender (females), n(%)	470(39)
Body mass index, kg/m ²	30±7.2
Hypertension, n(%)	734(61)
Diabetes mellitus, n(%)	549(45)
Smoking, n(%)	306(25)
Human immunodeficiency virus infection, n(%)	79(7)
Asthma, n(%)	154(13)
Chronic obstructive pulmonary disease, n(%)	119(10)
Chronic liver disease, n(%)	7 (0.5)
Hepatitis B virus infection, n(%)	4(0.3)
Hepatitis C virus infection, n(%)	50(4)
Congestive heart failure, n(%)	117(10)
Coronary artery disease, n(%)	125(10)
Chronic kidney disease, n(%)	98(8)
End stage renal disease, n(%)	82(7)
Fever, n(%)	784(65)
Cough , n(%)	795(66)
Shortness of breath, n(%)	827(69)
Myalgia , n(%)	363(30)
Chest discomfort, n(%)	149(12)
Atypical Symptoms, n(%)	411(34)
Time from symptoms to hospital presentation , days	5.8±5.5
Length of hospital stay, days	8±7
Hemoglobin (g/dL)	13±2.2
Platelets, (10 ³ /uL)	220.8±102.6
White cell count (10 ³ /uL)	8.6±6.9
Neutrophils (10 ³ /uL)	6.8±4
Lymphocytes (10 ³ /uL)	1.24±5.3
D-Dimer (ng/ml)	3080±9847
Lactate dehydrogenase (units/L)	582±393
High sensitivity C-reactive protein (mg/L)	142±112
Ferritin (mg/ml)	1153±11597
Lactate (mmol/L)	2.3±1.9
PT (seconds)	14±10.5
PTT (seconds)	32.2±7.8
Cratinin (mg/dL)	1.96±2.6
Alanine aminotransferase (units/L)	44.±69
Aspartate aminotransferase (units/L)	71.1±115
Alkaline phosphatase (units/L)	95±89
Total bilirubin (g/dL)	0.62±0.73
Combined bilirubin (g/dL)	0.27±0.46
Total protein, (g/dL)	7±0.8
Serum albumin, (g/dL)	3.6±0.6
Pro-calcitonin, (ng/ml)	2.6±10.2
Hydroxychloroquine, n (%)	918(76)
Tocilizumab, n (%)	80(7)
Need for mechanical ventilation, n (%)	485(40)
Mortality, n (%)	418(35)

Supplementary table 2: Patients with abnormal laboratory values overall in in the subgroups

	Normal range	All Patients (n=157)	Age≤55 (n=80)	Age>55 (n=77)	p-value χ^2
Hemoglobin (g/dL)	(12-15)	52(33%)*	26 (33%,)	26 (34%)	0.721
Platelets, (103/uL)	(150-450)	31(20%)**	20 (25%,)	11 (14%)	0.292
White cell count (103/uL)	(4-10)	54(34%***	26 (33%)	28 (36%)	0.343
Neutrophils (103/uL)	(1.5-8)	50(32%****	25 (31%)	25 (32%)	0.260
Lymphocytes (103/uL)	(0.5-5)	34(22%,0.42±0.09)\$	13 (16%)	21 (27%)	0.042
Prothrombin time (seconds)	≤13.5	56(36%, 15±1.4)	25 (31%)	31 (40%)	0.166
Activated Partial thromboplastin time (seconds)	≤36	22(14%, 41±7.2)	14 17(%)	8 (10%)	0.365
Creatinine (mg/dL)	≤1.1	49(31%, 1.52±0.7)	20(25%)	29 (38%)	0.037
Alanine transaminase (units/L)	≤56	39(25%, 102±48)	22 (28%)	17 (22%)	0.313
Aspartate transaminase (units/L)	≤40	84 (54%, 85±61)	37 (46%)	47 (61%)	0.06
Alkaline phosphatase (units/L)	≤140	14(9%, 228±159)	7 (9%)	7 (9%)	0.976

*16 patients were anemic (10.6±1), and 36 patients had erythrocytosis (16.2±1.2)

**27 patients had thrombocytopenia (116±30.8), and 4 patients had thrombocytosis (576±73, values were 523, 543, 554, 684)

***43 patients had leukocytosis (13.3±3) and 11 patients had lymphopenia (3.1±0.7)

****48 patients had neutrophilia (11.4±2.9), and 2 patients had neutropenia and the values were 0.5 and 1.4

\$ all patients had lymphopenia